This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ligand Pharmaceuticals Inc (LGND)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash and Equivalents 11.64M 12.38M 7.04M 3.35M
Receivables 6.55M 8.94M 12.31M 13.60M
Inventories 1.39M 1.70M 1.30M 0.00
Other Current Assets 959.00K 0.00 1.34M 720.00K
Total Current Assets 24.88M 23.82M 32.23M 37.02M
Property, Plant & Equipment, Gross 4.74M 5.67M 5.23M 9.73M
Accumulated Depreciation & Depletion 3.87M 4.88M 4.77M 9.17M
Property, Plant & Equipment, Net 867.00K 788.00K 455.00K 559.00K
Intangibles 57.67M 55.91M 57.44M 12.95M
Other Non-Current Assets 9.06M 11.49M 17.33M 25.03M
Total Non-Current Assets 79.83M 80.44M 90.12M 38.54M
Liabilities & Shareholder Equity
Total Assets 104.71M 104.26M 122.35M 75.56M
Accounts Payable 3.95M 5.85M 11.06M 8.60M
Short Term Debt 0.00 0.00 10.00M 0.00
Other Current Liabilities 8.85M 7.72M 13.08M 13.33M
Total Current Liabilities 28.94M 35.44M 43.64M 33.49M
Long Term Debt 0.00 13.44M 20.29M 22.85M
Deferred Income Taxes 1.10M 334.00K 2.52M 372.00K
Other Non-Current Liabilities 25.06M 28.56M 47.25M 23.70M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 26.16M 42.34M 70.06M 46.92M
Total Liabilities 55.10M 77.78M 113.70M 80.41M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 49.61M 26.48M 8.65M -4.85M
Common Par 21.00K 21.00K 21.00K 21.00K
Additional Paid In Capital 718.02M 751.50M 732.68M 729.27M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -671.34M -682.76M -681.77M -691.95M
Treasury Stock 0.00 -42.28M -42.28M -42.22M
Other Equity Adjustments 2.91M 0.00 0.00 31.00K
Total Capitalization 49.61M 39.93M 28.93M 18.00M
Total Equity 49.61M 26.48M 8.65M -4.85M
Total Liabilities & Stock Equity 104.71M 104.26M 122.35M 75.56M
Total Common Shares Outstanding 20.47M 20.16M 19.56M 19.51M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 1.12M 1.12M 1.11M
Basic Weighted Shares Outstanding 20.31M 19.85M 19.66M 19.61M
Diluted Weighted Shares Outstanding 20.75M 19.85M 19.71M 19.61M
Number of Employees 20 21 21 31
Number of Part-Time Employees 0 0 0 0

LGND Ligand Pharmaceuticals Inc

Analysts Ratings for LGND

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 5 4 5
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

LGND Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs